MEDPMedpace Holdings, Inc.
Services-Commercial Physical & Biological Research
- Revenue
- $2.5B
- 20% YoY
- Operating margin
- 21.1%
- 0.2% YoY
- EBITDA
- $562M
- 18% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.0×
- −$543M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear158% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowFired129% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear29% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.5B | $1.9B | $2.1B | $2.5B | 20% |
| Operating income | $199M | $279M | $337M | $447M | $535M | 20% |
| Net income | $182M | $245M | $283M | $404M | $451M | 12% |
| Operating cash flow | $263M | $388M | $433M | $609M | $713M | 17% |
| Capex | $28M | $37M | $37M | $37M | $31M | 14% |
| Stock-based comp | $14M | $21M | $21M | $26M | $35M | 36% |
| Buybacks | $62M | $848M | $144M | $170M | $917M | 440% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $139M · 13
- Net
- −$139M
Pay vs performance
No pay-versus-performance disclosure yet.